Skip to content

Studying how the different sub-types of Hepatitis E virus affects people with acute Hepatitis, along with what happens to them clinically: A small-scale research project conducted in West Bengal

Molecular characterization of Hepatitis E virus causing acute hepatitis and the clinical outcomes: a pilot study in West Bengal - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/05/066707
Enrollment
60
Registered
2024-05-03
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B172- Acute hepatitis E

Interventions

Control Intervention1: NIL: NIL

Sponsors

ICMR NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES INTRAMURAL GRANT
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Clinical suspicion of hepatitis with or without hyperbilirubinemia. 2.Any age 3.Serologically proven hepatitis E infection with detectable Anti HEV IgM antibody irrespective of the presence of other causative factors for hepatitis 4.First visit within 3 weeks of onset of symptoms

Exclusion criteria

Exclusion criteria: 1.Drug induced hepatitis 2.Any other cases of jaundice where Anti HEV IgM antibody is absent

Design outcomes

Primary

MeasureTime frame
1.Recovered: Liver function within normal limit in the final follow up, no subjective symptom, 2.Recovered with complications or other organ involvement 3.Recovering: Liver enzymes up to 3 times of the upper normal limit in the final follow up, no/ minimal subjective symptom, 4.Not recovered: Any one or more of persistent symptoms with persistent elevation of liver enzymes, progression to chronic illness in radiological or clinical diagnosis, liver failure with or without coagulopathy 5.Death Timepoint: The patients will be observed in three different time frames. 1.The first visit of the patient will be considered as baseline; this should be within 3 weeks of onset of the symptoms. 2.The second (follow up) visit will be done at 6 weeks of the first visit. 3.The third (follow up) visit will be done at 12 weeks of the first visit.

Secondary

MeasureTime frame
NATimepoint: NA

Countries

India

Contacts

Public ContactDr Sandip Mukhopadhyay

ICMR-NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES

sandipcmcl@gmail.com9888821984

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026